March 4, 2015
Chugai Pharmaceutical and the US-based biotechnology company Athersys Inc. said on March 2 that the pair has entered into an exclusive license agreement to develop and commercialize Athersys’s proprietary cell therapy product MultiStem for the treatment of ischemic stroke in...read more